FDA Denies That Four Volunteers Developed Bell's Palsy From Pfizer's Covid-19 Vaccine Shot
The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) have issued a joint statement urging states to “pause” the use of the Johnson and Johnson COVID-19 vaccine after those who received it experienced severe blood clotting.
The statement reads, in part:
CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.
The statement called the side effect “extremely rare” and said the CDC would convene a meeting of the Advisory Committee on Immunization Practices (ACIP) tomorrow to review the cases further. The FDA will review the CDC’s analysis and also plans to investigate the cases. “Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” reads the statement.
In the past week, administration of the Johnson and Johnson vaccine was halted at four different locations in Georgia, Colorado, Iowa and North Carolina after numerous adverse reactions, such as fainting and lightheadedness, occurred.
Report: Biden Admin Working On Scannable Vaccine Passports
The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) have issued a joint statement urging states to “pause” the use of the Johnson and Johnson COVID-19 vaccine after those who received it experienced severe blood clotting.
The statement reads, in part:
CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.
The statement called the side effect “extremely rare” and said the CDC would convene a meeting of the Advisory Committee on Immunization Practices (ACIP) tomorrow to review the cases further. The FDA will review the CDC’s analysis and also plans to investigate the cases. “Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” reads the statement.
In the past week, administration of the Johnson and Johnson vaccine was halted at four different locations in Georgia, Colorado, Iowa and North Carolina after numerous adverse reactions, such as fainting and lightheadedness, occurred.